Eden Research (EDEN)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 2.40p
   
  • Change Today:
      0.000p
  • 52 Week High: 4.25p
  • 52 Week Low: 2.10p
  • Currency: UK Pounds
  • Shares Issued: 533.35m
  • Volume: 155,172
  • Market Cap: £12.80m

Eden Research's Ecovelex gets another temporary approval in Italy

By Josh White

Date: Monday 17 Nov 2025

LONDON (ShareCast) - (Sharecast News) - Eden Research said in an update on Monday that its bird-repellent maize seed treatment Ecovelex has received temporary approval in Italy for the 2026 growing season, ensuring farmers could continue to access it.
The AIM-traded firm said the authorisation, granted under EU Regulation 1107/2009, repeated the time-limited permission first introduced in 2023 and allowed it to sell Ecovelex while it awaited full EU-wide approval.

It said Ecovelex provides a sustainable solution to crop destruction caused by birds by emitting an unpleasant taste or odour that deters feeding without harming the animals.

Developed at Eden's Oxfordshire facility, the product uses the group's plant-derived active ingredients and its plastic-free Sustaine microencapsulation technology.

Eden had already registered the actives in the EU, US, Mexico and other markets.

"This most recent temporary approval effectively repeats the time-limited permitted use of Ecovelex in Italy, which was first introduced in 2023 on a temporary basis," said chief executive Sean Smith.

"It comes as welcome news to the many local maize farmers who depend on seeds treated with Ecovelex as one of the only viable solutions left to protect against bird infestation."

He added that the authorisation "enables Eden to sell Ecovelex whilst we await full EU-wide authorisation, which is expected in due course."

Eden submitted its regulatory dossier to Austria in 2023, acting as the EU's interzonal rapporteur member state.

Full authorisation was expected once the EU review was complete, after which individual member states would ratify or request additional information before issuing local approvals.

At 1100 GMT, shares in Eden Research were up 4.55% at 2.3p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Eden Research Market Data

Currency UK Pounds
Share Price 2.40p
Change Today 0.000p
% Change 0.00 %
52 Week High 4.25p
52 Week Low 2.10p
Volume 155,172
Shares Issued 533.35m
Market Cap £12.80m

Eden Research Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
10.18% below the market average10.18% below the market average10.18% below the market average10.18% below the market average10.18% below the market average
17.07% below the sector average17.07% below the sector average17.07% below the sector average17.07% below the sector average17.07% below the sector average
Price Trend
56.69% below the market average56.69% below the market average56.69% below the market average56.69% below the market average56.69% below the market average
22.73% below the sector average22.73% below the sector average22.73% below the sector average22.73% below the sector average22.73% below the sector average
Income Not Available
Growth
55.15% above the market average55.15% above the market average55.15% above the market average55.15% above the market average55.15% above the market average
58.62% above the sector average58.62% above the sector average58.62% above the sector average58.62% above the sector average58.62% above the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Eden Research Dividends

No dividends found

Trades for 05-Dec-2025

Time Volume / Share Price
16:03 100,000 @ 2.10p
13:43 172 @ 2.30p
13:12 55,000 @ 2.47p

Eden Research Key Personnel

CFO Alexander John Abrey
CEO Sean M. Smith

Top of Page